News of the WeekBiomedicine

FDA Weighs Using Tumor Cell Lines for Vaccine Development

See allHide authors and affiliations

Science  17 Sep 1999:
Vol. 285, Issue 5435, pp. 1826-1827
DOI: 10.1126/science.285.5435.1826

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


A technique for making vaccines that has been off limits in the United States for 40 years is now getting a second look from the U.S. Food and Drug Administration (FDA). Experts in cell biology, retrovirology, cancer, and vaccinology gathered in Rockville, Maryland, on 7 to 10 September to advise the FDA and other health agencies on the risks of using "immortal" and tumor-derived cells to generate viral particles for vaccines.